In summary, our studies point to drugs that modulate P-eIF2α either alone or in combination with PARPis or ionizing radiation as novel means for treatment of PED-GBM and suggest that elucidation of their downstream effectors can reveal additional cellular components that can be targeted for the treatment of PED-GBM. This evidence concerns the gene EIF2A and glioblastoma.